Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12212055 | 0.88 | MAPT (0.62) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL10126836 | 0.86 | MAPT (0.54) | MAPTSIRT6ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5949625 | 0.85 | MAPT (0.53) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL21001151 | 0.84 | MAPT (0.71) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3925665 | 0.84 | MAPT (0.71) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL29164357 | 0.84 | MAPT (0.58) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL22031656 | 0.82 | MAPT (0.56) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL22028444 | 0.80 | SIRT6 (0.61) | MAPTSIRT6ALDH1A1LMNAKMT2A | |
| SCHEMBL3937215 | 0.80 | MAPT (0.72) | MAPTSIRT6ALDH1A1LMNAMEN1 | |
| SCHEMBL18341999 | 0.79 | ADRA2C (0.53) | MAPTALDH1A1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113214287-B | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2023-10-20 | — | — | CN | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| EP-3322711-B1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIV HEALTH NETWORK (CA) | 2021-03-10 | — | — | EP | disclosed |
| EP-3322711-B1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIV HEALTH NETWORK (CA) | 2021-03-10 | — | — | EP | disclosed |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20180179221-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2018-06-28 | — | — | US | disclosed |
| US-20180179221-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2018-06-28 | — | — | US | disclosed |
| US-20180179221-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2018-06-28 | — | — | US | disclosed |
| EP-3322711-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | University Health Network (CA) | 2018-05-23 | — | — | EP | disclosed |
| WO-2016205942-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059832-B2 | HPK1 inhibitors and methods of using same | PDXK, PDK3, PDK2 | MAPT 3682/4885SIRT6 2166/4885ALDH1A1 2442/4885 |
| US-20180179221-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | MAPT 3682/4885SIRT6 2166/4885ALDH1A1 2442/4885 |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | MAPT 3802/4885SIRT6 2248/4885ALDH1A1 2458/4885 |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | MAPT 3682/4885SIRT6 2166/4885ALDH1A1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.